StocksMedium•6 October 2026•
1 min read
OS Therapies Reports Positive Phase 2b Survival Data for Herlystic
Key Facts
1OS Therapies achieved a 72.7% three-year overall survival rate for Herlystic-treated patients versus 45.8% for the historical control group.
2The company is preparing to complete submissions for early market access in the U.S., U.K., Europe, and Australia.
OS Therapies achieved a 72.7% three-year overall survival rate for patients treated with Herlystic, compared to 45.8% for the historical control group. Newsfile Corp reported that these results from the Phase 2b trial in pulmonary metastatic osteosarcoma demonstrated a statistically significant survival benefit.
The company is preparing to complete submissions for early market access in the U.S., U.K., Europe, and Australia following the trial success. Regarding market performance, OSTX closed at $1.6 on October 5, 2026, after reaching a day high of $1.63 and a low of $1.57 during the session.